These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23284776)

  • 41. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
    Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
    Owens DR; Traylor L; Dain MP; Landgraf W
    Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
    Jacober SJ; Rosenstock J; Bergenstal RM; Prince MJ; Qu Y; Beals JM
    Diabetes Obes Metab; 2014 Apr; 16(4):351-6. PubMed ID: 24719911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
    Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
    J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Alhmoud EN; Saad MO; Omar NE
    Front Endocrinol (Lausanne); 2023; 14():1285147. PubMed ID: 38313835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials.
    Mannucci E; Caiulo C; Naletto L; Madama G; Monami M
    Endocrine; 2021 Dec; 74(3):508-517. PubMed ID: 34599695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin glargine in the treatment of type 1 and type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
    Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
    Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
    Blonde L; Baron MA; Zhou R; Banerji MA
    Postgrad Med; 2014 May; 126(3):172-89. PubMed ID: 24918802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
    Martin ; Zhou Y; Takagi T; Tian YS
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
    Chang CH; Chuang LM
    J Diabetes Investig; 2018 Jul; 9(4):728-730. PubMed ID: 29140602
    [No Abstract]   [Full Text] [Related]  

  • 53. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes.
    Shaefer CF; Reid TS; Dailey G; Mabrey ME; Vlajnic A; Stuhr A; Stewart J; Zhou R
    Postgrad Med; 2014 Oct; 126(6):93-105. PubMed ID: 25414938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
    Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insufficient evaluation of adverse events is not a proof of safety.
    Hemkens LG; Grouven U; Bender R; Sawicki PT
    Diabetologia; 2010 Apr; 53(4):790-2; author reply 793-4. PubMed ID: 20099058
    [No Abstract]   [Full Text] [Related]  

  • 58. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes mellitus and the risk of cancer.
    Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
    Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.